aplitabart + venetoclax + azacitidine

**Aplitabart + venetoclax + azacitidine** is a combination investigational regimen for oncological indications, combining aplitabart (an IgM monoclonal antibody targeting death receptor 5/DR5), venetoclax (a BCL-2 inhibitor), and azacitidine (a pyrimidine nucleoside analog and DNA methyltransferase inhibitor)[1][2][5]. - **Aplitabart** (IGM-8444) is developed by IGM Biosciences and acts as a TRAIL receptor 2 (DR5) agonist, inducing apoptosis in malignant cells[1]. - **Venetoclax** is a small molecule targeting the anti-apoptotic protein BCL-2, used to induce cell death in cancers such as leukemia[5]. - **Azacitidine** is a DNA hypomethylating agent, which incorporates into DNA/RNA, impeding abnormal cell proliferation and restoring normal hematopoiesis in conditions like AML and MDS[2][4][6]. This combination is being studied for synergistic pro-apoptotic effects in various relapsed/refractory hematologic malignancies and solid tumors, notably acute myeloid leukemia, colorectal carcinoma, and lymphoma[5][7].

Brand names

Azacitidine AccordAzacitidine BetapharmAzacitidine KabiAzacitidine Mylan

Other names

aplitabartIGM-8444IGM8444IGM 8444venetoclaxazacitidine